Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000812052 | SCV000952354 | pathogenic | Deafness-lymphedema-leukemia syndrome; Monocytopenia with susceptibility to infections | 2023-09-30 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg337*) in the GATA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GATA2 are known to be pathogenic (PMID: 21670465, 23223431). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with clinical features of GATA2 deficiency (PMID: 21892158, 23502222, 27894982). ClinVar contains an entry for this variant (Variation ID: 29719). For these reasons, this variant has been classified as Pathogenic. |
Molecular Pathology Research Laboratory, |
RCV001542112 | SCV001760780 | pathogenic | Deafness-lymphedema-leukemia syndrome; GATA2 deficiency with susceptibility to MDS/AML | 2021-07-06 | criteria provided, single submitter | curation | PVS1, PS4, PM2 |
Oxford Medical Genetics Laboratories, |
RCV003325944 | SCV003853412 | pathogenic | Monocytopenia with susceptibility to infections | 2023-03-23 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000984812 | SCV003918731 | pathogenic | not provided | 2023-04-11 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 23502222, 33684095, 21892158, 32770553, 34529785, 30538114, 27894982, 35753512) |
OMIM | RCV000022571 | SCV000043860 | pathogenic | Deafness-lymphedema-leukemia syndrome | 2011-09-04 | no assertion criteria provided | literature only | |
Prevention |
RCV003891441 | SCV001132693 | pathogenic | GATA2-related disorder | 2024-03-04 | no assertion criteria provided | clinical testing | The GATA2 c.1009C>T variant is predicted to result in premature protein termination (p.Arg337*). This variant has been reported to be causative for GATA2-related disorders including MonoMAC, and primary lymphedema and predisposition to acute myeloid leukemia (Ostergaard et al. 2011. PubMed ID: 21892158; Hsu et al. 2013. PubMed ID: 23502222). This variant is not present in a large population database and has been interpreted as pathogenic in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/29719/). Nonsense variants in GATA2 are expected to be pathogenic. This variant is interpreted as pathogenic. |